Comparative Pharmacology
Head-to-head clinical analysis: ENHERTU versus MARGENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENHERTU versus MARGENZA.
ENHERTU vs MARGENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 IgG1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent